Checkpoint inhibitor nivolumab may be an effective treatment for refractory Burkitt lymphoma, a rare and aggressive form of cancer. This is an important development for patients whose cancer cells remain resistant to usual ...
Oct 27, 2020
0
3
(HealthDay)—High levels of physical activity may lower the risk for developing lymphoma, according to a review/meta-analysis published online Oct. 6 in BMC Cancer.
Oct 14, 2020
0
4
The National Comprehensive Cancer Network (NCCN) today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Hodgkin Lymphoma. Hodgkin lymphoma is one of the most curable ...
Sep 28, 2020
0
3
The National Institute for Health and Care Excellence (NICE) has recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Aug 21, 2020
0
1
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical ...
Jul 23, 2020
0
3
A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment. In the case of the blood cancer anaplastic large cell lymphoma (ALCL), an international team ...
Jul 15, 2020
0
0
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published today in the New England Journal of Medicine. This academic trial involved two international cooperative groups—the ...
Jun 4, 2020
0
1
Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated ...
Jun 4, 2020
0
0
(HealthDay)—For adolescent and young adult (AYA) patients with Hodgkin lymphoma (HL), treatment strategies differ, but outcomes are equivalent with treatment at pediatric and adult centers, according to a study published ...
May 29, 2020
0
2
A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by ...
May 11, 2020
0
8
